Cutaneous adverse reactions after COVID‐19 vaccines in a cohort of 2740 Italian subjects: An observational study
Open accessAbstract
An in‐depth characterization of the incidence, morphology, and onset of COVID‐19‐vaccines cutaneous adverse reactions is currently lacking. The existing literature on COVID‐19 vaccination‐related cutaneous adverse reactions largely focused on messenger RNA vaccines and mainly included type 1 hypersensitivity reactions, such as urticaria and angioedema. Other cutaneous manifestations are still poorly characterized and have been classified as delayed hypersensitivity rash. Our prospective observational study on a sample of 2740 subjects who underwent the COVID‐19 vaccination aimed at defining the prevalence of cutaneous adverse reactions and at identifying their timing of onset and their correlation with the administered dose. Vaccine‐related cutaneous adverse reactions occurred in 50 subjects. Patients were asked to complete a questionnaire on the type of COVID‐19 vaccine received, the time of onset of cutaneous reactions, and the dates of administration. Out of 2740 individuals who received the COVID‐19 vaccination, 50 were diagnosed with cutaneous adverse reactions to vaccine, after the first dose in 28 patients, after the second in 20, and after both in two. We reported localized injection site erythema in 12 patients and generalized cutaneous reactions in 38 patients. Our study shows that cutaneous adverse reactions to COVID‐19 vaccination are not common and most often occur after the first dose, recurring infrequently after the second dose. These reactions are usually easily manageable and, even in severe generalized cases, oral antihistamines and corticosteroids were sufficient for resolution. Therefore, except for immediate hypersensitivity reactions, cutaneous adverse reactions do not represent a contraindication to the completion of the vaccination cycle.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Four potentially vaccine-related rashes were reported, too few to determine whether the pattern was similar to that observed in adult BNT162b2 recipients.
“Four potentially vaccine-related rashes were reported, too few to determine whether the pattern was similar to that observed in adult BNT162b2 recipients.31”
From Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2022) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1× · see citing works
“The first COVID-19 vaccine, ComirnatyTM, was granted conditional marketing approval (CMA) on December 21, 2020.(1) Authorization for SpikevaxTM (previously COVID-19 Vaccine Moderna), for VaxzevriaTM (previously COVID-19 Vaccine AstraZeneca) and for COVID-19 Vaccine Janssen followed on Received: 23 August 2021 Revised:…”
BackgroundEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works
McMahon, D. E., Amerson, E. H., Rosenbach, M. A., Lipoff, J. B., Moustafa, D., Tyagi, A., Desai, S. R., French, L. E., Lim, H. W., THIERS, B. H., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.03.092 · Cited by 808 · see citing works
Pityriasis lichenoides and its subtypes
Bowers, S., & Warshaw, E. M. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.07.058 · Cited by 266 · see citing works
Kounis, N. G., Koniari, I. C., GREGORIO, C. D., Velissaris, D., Petalas, K., Brinia, A., Assimakopoulos, S. F., Gogos, C., Kouni, S. N., Kounis, G. N., et al. (2021) · Vaccines · doi:10.3390/vaccines9030221 · Cited by 192 · see citing works
Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine
Johnston, M. S., Galan, A., Watsky, K. L., et al. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.1214 · Cited by 127 · see citing works
The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
Cavaleri, M., Enzmann, H., Straus, S., & Cooke, E. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00085-4 · Cited by 98 · see citing works
Larson, V. A., Seidenberg, R., Caplan, A. S., et al. (2021) · Journal of Cutaneous Pathology · doi:10.1111/cup.14104 · Cited by 95 · see citing works
Cutaneous adverse reactions after m‐RNA COVID‐19 vaccine: early reports from Northeast Italy
Farinazzo, E., Ponis, G., Zelin, E., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17343 · Cited by 58 · see citing works
Pityriasis rosea‐like eruptions following vaccination with BNT162b2 mRNA COVID‐19 Vaccine
Cyrenne, B. M., Al‐Mohammedi, F., DeKoven, J. G., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17342 · Cited by 47 · see citing works
CD30+ Lymphomatoid Drug Reactions
Pulitzer, M. P., Nolan, K. A., Oshman, R. G., et al. (2013) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e31826bc1e5 · Cited by 38 · see citing works
Chello, C., Carnicelli, G., Sernicola, A., Gagliostro, N., Paolino, G., Fraia, M. D., Faina, V., Muharremi, R., & Grieco, T. (2020) · International Journal of Dermatology · doi:10.1111/ijd.14891 · Cited by 32 · see citing works
Self-citationRestivo, V., Candore, G., Barrale, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9050412 · Cited by 28 · see citing works
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Cutaneous Adverse Reactions: A Review
Alpalhão, M., Silva, J. M., & Filipe, P. (2021) · Dermatitis · doi:10.1097/der.0000000000000755 · Cited by 12 · see citing works
Stingeni, L., Board Members of SIDeMaST, Bianchi, L., et al. (2021) · Italian Journal of Dermatology and Venereology · doi:10.23736/s2784-8671.21.06992-3 · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
Walter, E. B., Talaat, K. R., Sabharwal, C., Gurtman, A., Lockhart, S., Paulsen, G. C., Barnett, E. D., Muñoz, F. M., Maldonado, Y., Pahud, B. A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116298 · Cited by 593 · see citing works
- Authors
- Grieco, T., Maddalena, P., Sernicola, A., Muharremi, R., Basili, S., Alvaro, D., Cangemi, R., Rossi, A., & Pellacani, G.
- Affiliations
- Sapienza University of Rome (IT)
- Corresponding author
- Sernicola, Alvise
- ORCID
- Venue
- Dermatologic Therapy
- Publisher
- Wiley
- Published
- 2021-10-13
- Volume
- 34
- Issue
- 6
- Pages
- e15153-e15153
- ISSN
- 1396-0296 (ISSN-L)
- 1529-8019
- PMC
- PMC8646410
- OpenAlex
- W3202912449
- Cited by
- 52
- References
- 15
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 7 · 2023: 11 · 2022: 27 · 2021: 3
- FWCI
- 10.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Dermatologic Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatological and COVID-19 studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
- Keywords
- COVID-19 vaccines, cutaneous adverse events, vaccine safety, injection site erythema, immediate hypersensitivity, mRNA vaccines, vaccine contraindications, antihistamines, corticosteroids
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, Humans, Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
